

Dana-Farber Cancer Institute & the Jimmy Fund
Division of Philanthropy
2018 PMC Pie Chart Detail

Below are categories within the pie chart depicting the \$56 million gift from the Pan-Mass Challenge in 2018, along with short descriptive paragraphs explaining each pie chart item.

➤ **Pediatric Oncology, \$11.6M**

The Department of Pediatric Oncology at Dana-Farber is advancing research and care to improve outcomes for young patients with cancer. Department faculty are spearheading studies to reveal the biological drivers of pediatric brain cancers, solid tumors, and hematologic malignancies; identifying patients who are at-risk for disease progression or relapse; and leading efforts to improve pediatric cancer care in countries around the world—all while addressing the full range of patient and family needs. Additionally, Dana-Farber's new Center for Pediatric Cancer Therapeutics works to overcome the toughest challenges in therapeutic development while accelerating new treatments through clinical trials.

➤ **Longwood Center: State-of-the-Art Research Labs, \$10.9M**

Opened in 2015, the Longwood Center is a hub of creative, collaborative, and cutting-edge science that houses the Institute's robust cancer chemical biology and drug development programs. Leveraging this state-of-the-art facility and sophisticated technologies, investigators are propelling groundbreaking research to accelerate the discovery and delivery of potentially lifesaving therapies to patients.

➤ **Precision Cancer Medicine, \$5.7M**

Dana-Farber is a leader in precision cancer medicine—a growing field in which researchers are uncovering new information about the genetic makeup of cancer in order to find more effective treatments. Through *Profile*, the Institute's flagship precision medicine initiative, every patient who comes to Dana-Farber has the opportunity for his/her tumor to be analyzed for known cancer-promoting genetic mutations. Clinically relevant information from the test can be shared with doctors to help guide treatment. More than 25,000 patient tumors have been analyzed, making *Profile* one of the largest and most comprehensive patient-based genomic projects in the world.

➤ **Adult Oncology, \$4.4M**

Driven by a balanced commitment to scientific and clinical excellence that is unique among cancer centers, Dana-Farber is pioneering novel detection, prevention, and treatment strategies while delivering comprehensive and compassionate care. Dana-Farber has been the top ranked cancer hospital in New England in *US News & World Report* for 18 consecutive years, and is the only cancer center in the country ranked in the top four for both adult and pediatric oncology programs.

➤ **Hematologic Oncology, \$4.3M**

**Dana-Farber Cancer Institute & the Jimmy Fund
Division of Philanthropy
2018 PMC Pie Chart Detail**

Dana-Farber's Center for Hematologic Oncology is answering key questions about and improving treatments for all types of blood cancers including leukemia, lymphoma, multiple myeloma, and Waldenström's macroglobulinemia, as well as related disorders of the blood, such as aplastic anemia and myelodysplasia. The Center also includes the Institute's Stem Cell Transplantation Program, which was established in 1972 and is one of the largest and most experienced in the world. The Center continues to expand its scientific and clinical capabilities in order to pursue promising research opportunities and accommodate increased patient volume.

➤ **Data Sciences, \$2.9M**

Dana-Farber's Department of Data Sciences leverages the latest knowledge and tools from computational science to propel cancer research and provides investigators with access to expert quantitative scientists. The department is a leader in the design and implementation of innovative preclinical and clinical trials, analysis of patient genomic data, development of strategies to overcome drug resistance, and the training of biostatisticians and computational biologists, among other activities.

➤ **Cancer Biology, \$2.4M**

Dana-Farber's Department of Cancer Biology studies fundamental problems in biology that affect cancer, to translate laboratory findings into more effective treatments. Researchers are driving early-stage drug discovery and testing; studying the genetics of brain development; and advancing breakthrough investigations in energy and homeostasis, structural biology, systems biology, and women's cancers.

➤ **Gastrointestinal Oncology, \$2.2M**

The Center for Gastrointestinal Oncology at Dana-Farber is dedicated to the study and treatment of all types of gastrointestinal cancer, including colorectal, esophageal, neuroendocrine, pancreatic, stomach, and liver cancers. In addition to providing personalized patient care, the Center's multidisciplinary team of experts is advancing an ambitious research platform to uncover the biological underpinnings of tumors, identify new genetic targets, and examine lifestyle factors associated with disease progression.

➤ **Immuno-Oncology, \$2M**

• **Center for Immuno-Oncology**

Dana-Farber's Center for Immuno-Oncology (CIO) is extending the benefits of immunotherapy – which leverages the body's natural defenses against cancer – to a greater number of patients. Harnessing the Institute's collaborative strength, CIO physician-scientists are studying how the immune system interacts with cancer cells,

Dana-Farber Cancer Institute & the Jimmy Fund
Division of Philanthropy
2018 PMC Pie Chart Detail

increasing the number of clinical trials, introducing novel technologies into research, and improving immunotherapy treatment strategies across multiple cancers.

- **Center for Precision Immuno-Oncology**

Dana-Farber is building upon its global leadership in cancer precision medicine and immunotherapy to revolutionize cancer care through its new Center for Precision Immuno-Oncology (CPIO). Fueled by expert faculty, extensive collaborations, and a robust technology platform, the CPIO combines an analysis of the immune status of patients and their cancers along with their genetic profiles to develop safe, effective, and lasting immune responses against more cancer types.

- **Other Designations, \$1.8M**

PMC support is allocated to additional areas including Immunology & Virology, Joint Ventures, Oncologic Pathology, Population Sciences, and the Leonard P. Zakim Center for Integrative Therapies and Healthy Living. The Zakim Center improves patient quality of life and outcomes by offering a range of complementary therapies, such as acupuncture, exercise programs, massage, meditation, and nutrition education.

- **Neuro-Oncology, \$1.6M**

Dana-Farber's Center for Neuro-Oncology mobilizes interdisciplinary teams of experts to provide individualized care for patients with tumors of the brain or spinal cord, as well as for neurologic complications of cancer and its treatments. Center investigators are developing novel targeted drugs, immunotherapies, and combination approaches for treating a range of common and rare neurologic malignancies. Patients also have access to a broad spectrum of clinical trials of next-generation therapies.

- **Nursing and Patient Care, \$1.4M**

The Department of Nursing and Patient Care Services at Dana-Farber mobilizes highly-skilled nurses who provide clinical expertise, emotional support, and patient-centered care. Additionally, nurse-scientists are improving communication between patients and doctors, reducing healthcare disparities, and developing evidence-based interventions to manage cancer symptoms. In recognition of its nursing excellence, Dana-Farber has received the prestigious Magnet designation from the American Nurses Credentialing Center three times.

- **Psychosocial Oncology and Palliative Care, \$1.4M**

The Department of Psychosocial Oncology and Palliative Care at Dana-Farber aims to alleviate the burden of cancer and improve quality of life for patients and families by

Dana-Farber Cancer Institute & the Jimmy Fund
Division of Philanthropy
2018 PMC Pie Chart Detail

providing one-on-one consultations, support groups, and other personalized services. An integrated team of specially trained physicians, nurses, pharmacists, psychologists, and social workers delivers joint care and supports each patient's unique needs from diagnosis through treatment and into survivorship.

➤ **Radiation Oncology, \$1.2M**

The Institute's Department of Radiation Oncology provides individualized radiation treatment for patients with breast cancer, gastrointestinal cancers, genitourinary cancers, head and neck cancers, sarcomas, thoracic cancer, lymphoma, and cancers of the central nervous system. The department also advances basic and clinical research to enhance diagnostic approaches and develop more precise radiation therapies.

➤ **Imaging, \$1.0M**

The Department of Imaging at Dana-Farber conducts transformative imaging research that enables breakthrough discoveries. Using state-of-the-art technology, including a dedicated cancer research cyclotron, cancer imaging specialists are delivering exceptional cancer imaging expertise for patients, providers, and investigators. Imaging experts are collaborating with basic scientists and clinical investigators across and beyond Dana-Farber to accelerate drug discovery and clinical trials, and train the next generation of technologists.

➤ **Sarcoma and Bone Cancers, \$600K**

Dana-Farber's Center for Sarcoma and Bone Oncology is a world leader in studying, diagnosing, and treating these diverse and complex tumors. Researchers are revealing invaluable information about tumor biology, identifying the genetic mechanisms of disease progression, redefining sarcoma subtypes, and rapidly translating the latest discoveries into clinical trials to test novel therapies.

➤ **Women's Cancers, \$600K**

Dana-Farber's Susan F. Smith Center for Women's Cancers bridges compassionate care with world-class basic and clinical research. Susan F. Smith Center faculty are making strides against breast and gynecologic cancers by expanding the use of immunotherapy, developing targeted and combination treatments, analyzing disease risk, conducting prevention studies, and advancing new strategies for combating drug-resistant and metastatic tumors.